CARLSBAD, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced its financial results for second quarter ended June 30, 2024.
All figures are in U.S. dollars.
Financial and Business Highlights
Management Commentary
Trent Northcutt, Chief Executive Officer of Aurora Spine, commented, “The second quarter of 2024 was a pivotal period for Aurora, with notable progress in both our financial performance and market penetration. Our strategic focus on expanding the sales force and targeting underserved markets has yielded strong results, as evidenced by our significant sales growth and improved profitability. We remain dedicated to pushing the boundaries of spinal technology, delivering superior clinical outcomes, and driving sustained financial success for our stakeholders.”
Financial Results
Revenue Growth: Total revenues for Q2 2024 reached $4.02 million, marking a 14.3% increase compared to $3.66 million in Q2 2023. The quarter benefited from strong demand in the pain management sector, particularly for the SiLO TFX and ZIP 51 implants, driven by targeted marketing, training, and product innovation.
Gross Margin Expansion: Gross margins improved to 62.4% in Q2 2024, up from 56.9% in the same period last year. The margin improvement is a direct result of the increased sales of proprietary products with higher profitability, particularly in markets with favorable pricing dynamics like ambulatory surgery centers.
Operating Expenses: Operating expenses for Q2 2024 were $2.74 million, up from $2.51 million in Q2 2023. The rise in expenses was primarily due to increased salary and travel costs associated with expanding the sales force, partially offset by reductions in research and development and professional fees.
EBITDAC Improvement: EBITDAC (a non-GAAP figure non IFRS measure defined as Earnings before Interest, Tax, Depreciation, Amortization and Stock based compensation) was $0.11 million, compared to a loss of $(0.16) million in Q2 2023. This improvement highlights Aurora’s ability to enhance profitability through efficient operations and a focus on high-margin product lines.
Reduced Net Loss: The Company reported a net loss of $(0.154) million for Q2 2024, significantly narrowing from a net loss of $(0.482) million in Q2 2023. Basic and diluted net loss per share improved to $(0.00) in Q2 2024 from $(0.01) in Q2 2023.
Full financial statements can be found on SEDAR at (www.sedarplus.ca).
SELECTED STATEMENT OF FINANCIAL POSITION INFORMATION
The following table summarizes selected key financial data.
| As at | June 30, 2024 | December 31, 2023 | December 31, 2022 |
| $ | $ | $ | |
| Cash | 518,546 | 766,829 | 423,401 |
| Receivables | 4,215,811 | 3,968,439 | 3,666,310 |
| Prepaid and other current assets | 185,106 | 204,173 | 186,800 |
| Inventory | 3,587,987 | 3,562,349 | 3,054,173 |
| Current assets | 8,507,450 | 8,501,790 | 7,330,684 |
| Notes receivable | 465,819 | 454,628 | - |
| Intangible assets | 850,048 | 753,180 | 881,354 |
| Property and equipment | 2,167,421 | 2,275,478 | 1,910,940 |
| Total assets | 11,990,738 | 11,985,076 | 10,122,978 |
| Current liabilities | 3,618,981 | 3,273,058 | 3,029,599 |
| Non-current liabilities | 3,448,161 | 3,414,695 | 2,773,919 |
| Share capital | 27,657,591 | 27,657,591 | 25,218,093 |
SELECTED QUARTERLY INFORMATION
The Company’s functional currency is the US dollar (USD). The functional currency of the Company’s US subsidiary Aurora is USD.
Operating results for each quarter for the last two fiscal years are presented in the table below.
| Quarters End | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | ||||||||
| $ | $ | $ | $ | $ | $ | $ | $ | |||||||||
| Revenue | 4,079,543 | 4,013,801 | 4,044,234 | 3,949,530 | 3,568,583 | 2,958,088 | 3,609,514 | 3,648,680 | ||||||||
| Cost of goods sold | (1,532,173 | ) | (1,529,538 | ) | (1,749,216 | ) | (1,592,530 | ) | (1,537,410 | ) | (1,429,987 | ) | (1,783,881 | ) | (1,706,677 | ) |
| Gross profit | 2,547,370 | 2,484,263 | 2,295,018 | 2,357,000 | 2,031,173 | 1,528,101 | 1,825,632 | 1,942,003 | ||||||||
| Operating expenses | 2,701,478 | 2,751,188 | 2,580,613 | 2,606,618 | 2,513,587 | 2,191,039 | 2,665,203 | 2,057,655 | ||||||||
| EBITDAC* | 105,522 | 117,171 | 109,734 | 120,796 | (163,660 | ) | (377,871 | ) | (358,311 | ) | 150,687 | |||||
| Net loss | (154,108 | ) | (266,925 | ) | (285,595 | ) | (249,618 | ) | (482,414 | ) | (662,938 | ) | (839,570 | ) | (115,652 | ) |
| Basic and diluted loss per share** | (0.00 | ) | (0.00 | ) | (0.00 | ) | (0.00 | ) | (0.01 | ) | (0.01 | ) | (0.01 | ) | (0.00 | ) |
* EBITDAC is a non-GAAP, non IFRS measure defined as Earnings before Interest, Tax, Depreciation, Amortization and Stock based compensation. This amount includes Gains (losses) on sale of property and equipment and Other income (expense).
** Outstanding options and warrants have not been included in the calculation of the diluted loss per share as they would have the effect of being anti-dilutive.
Second Quarter 2024 Conference Call Details
Date and Time: Friday, August 23, 2024, at 11:00 a.m. ET / 8:00 a.m. PT
Call-in Information: Interested parties can access the conference call by dialing (844) 861-5497 or (412) 317-5794.
Webcast: Interested parties can access the conference call via a live webcast, which is available via the following link: https://app.webinar.net/5xAJmW9XzV6.
Replay: A teleconference replay of the call will be available until August 30, 2024, at (877) 344-7529 or (412) 317-0088, replay access code 1299715. Additionally, a replay of the webcast will be available at https://app.webinar.net/5xAJmW9XzV6 for 90 days.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
| Last Trade: | C$0.31 |
| Daily Volume: | 0 |
| Market Cap: | C$24.000M |
April 02, 2025 October 24, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
